Arikayce
Payments companies reported to CMS as associated with Arikayce. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Arikayce, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Arikayce
These are the largest totals companies reported as associated with Arikayce. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Khabbaza | Akron, OH | Pulmonary Disease | $69,230.32 |
| David Griffith | Denver, CO | Infectious Disease | $62,300.55 |
| Andrew Dold | Dacula, GA | Infectious Disease | $56,699.71 |
| Juzar Ali | New Orleans, LA | Pulmonary Disease | $50,853.03 |
| Anas Hadeh | Weston, FL | Pulmonary Disease | $28,920.84 |
| Kevin Winthrop | Portland, OR | Infectious Disease | $24,647.33 |
| Wendi Drummond | Portland, OR | Infectious Disease | $24,022.36 |
| Shannon Kasperbauer | Denver, CO | Infectious Disease | $23,068.24 |
| Patrick Flume | Charleston, SC | Pulmonary Disease | $22,413.22 |
| Colin Swenson | Atlanta, GA | Pulmonary Disease | $21,710.97 |
Prescribed Arikayce?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.